The level of detail in this trial kick off Ann is the best any would come across on the ASX if not globally. This is not a small cap company level of Ann, probably better than even mega cap biotechs.
They have mentioned the trial design of each arm, statistical methods, dosages, timelines etc., as good as clinical trials listing at the same time quite readable. Leaves very little doubt or to imagination.
Well done mgmt & BOD. Stock price is not a reflection or a measure of the company.
Ann: Race Receives Governance Approval for AML EMD & MDS Trial, page-26
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
